Birgit S Geurts
Overview
Explore the profile of Birgit S Geurts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verkerk K, van der Wel T, Zeverijn L, Geurts B, Spiekman I, de Wit G, et al.
Clin Cancer Res
. 2024 Oct;
30(23):5323-5332.
PMID: 39352721
Purpose: To provide patients with MET-mutated advanced non-small cell lung cancer (METmut aNSCLC) access to crizotinib, further substantiate evidence of its efficacy and safety in this setting, and find potential...
2.
Zeverijn L, Geurts B, Battaglia T, van Berge Henegouwen J, de Wit G, Hoes L, et al.
Clin Cancer Res
. 2024 Jul;
30(19):4339-4351.
PMID: 39024037
Purpose: The treatment efficacy of nivolumab was evaluated in patients with advanced, treatment-refractory solid mismatch repair deficiency/microsatellite-instable (dMMR/MSI) tumors, and in-depth biomarker analyses were performed to inform precision immunotherapy approaches....
3.
van Berge Henegouwen J, Zeverijn L, Geurts B, Hoes L, van der Wijngaart H, van der Noort V, et al.
Clin Cancer Res
. 2024 Jun;
30(17):3937-3943.
PMID: 38926908
Purpose: Although eligibility criteria are essential in trial design, overly restrictive criteria contribute to low accrual and limited generalizability. To enhance trial inclusivity, there has been growing interest in broadening...
4.
F Haj Mohammad S, Timmer H, Zeverijn L, Geurts B, Spiekman I, Verkerk K, et al.
Acta Oncol
. 2024 May;
63:368-372.
PMID: 38779868
Background And Purpose: The Drug Rediscovery Protocol (DRUP) is a Dutch, pan-cancer, nonrandomized clinical trial that aims to investigate the efficacy and safety of targeted and immunotherapies outside their registered...
5.
Geurts B, Zeverijn L, van Berge Henegouwen J, van der Wijngaart H, Hoes L, de Wit G, et al.
J Pathol
. 2024 May;
263(3):288-299.
PMID: 38747304
In the Drug Rediscovery Protocol (DRUP), patients with cancer are treated based on their tumor molecular profile with approved targeted and immunotherapies outside the labeled indication. Importantly, patients undergo a...
6.
Geurts B, Zeverijn L, Leek L, van Berge Henegouwen J, Hoes L, van der Wijngaart H, et al.
Clin Cancer Res
. 2024 Apr;
30(17):3735-3746.
PMID: 38630551
Purpose: To evaluate the efficacy of pembrolizumab across multiple cancer types harboring different levels of whole-genome sequencing-based tumor mutational load (TML; total of nonsynonymous mutations across the genome) in patients...
7.
Battaglia T, Mimpen I, Traets J, Van Hoeck A, Zeverijn L, Geurts B, et al.
Cell
. 2024 Apr;
187(9):2324-2335.e19.
PMID: 38599211
Microbial communities are resident to multiple niches of the human body and are important modulators of the host immune system and responses to anticancer therapies. Recent studies have shown that...
8.
Spiekman I, Zeverijn L, Geurts B, Verkerk K, F Haj Mohammad S, van der Noort V, et al.
Eur J Cancer
. 2024 Mar;
202:113988.
PMID: 38471288
Background: In 2-5% of patients with colorectal cancer (CRC), human epidermal growth factor 2 (HER2) is amplified or overexpressed. Despite prior evidence that anti-HER2 therapy confers clinical benefit (CB) in...
9.
Verkerk K, Geurts B, Zeverijn L, van der Noort V, Verheul H, Haanen J, et al.
Lancet Reg Health Eur
. 2024 Mar;
39:100875.
PMID: 38464480
Background: The DRUG Access Protocol provides patients with cancer access to registered anti-cancer drugs that are awaiting reimbursement in the Netherlands and simultaneously collects prospective real-world data (RWD). Here, we...
10.
Spiekman I, Geurts B, Zeverijn L, de Wit G, van der Noort V, Roepman P, et al.
Oncologist
. 2023 Dec;
29(5):431-440.
PMID: 38109296
Background: The prognosis of malignant primary high-grade brain tumors, predominantly glioblastomas, is poor despite intensive multimodality treatment options. In more than 50% of patients with glioblastomas, potentially targetable mutations are...